Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Ther… Read more
Pelthos Therapeutics Inc. (PTHS) - Net Assets
Latest net assets as of September 2025: $58.25 Million USD
Based on the latest financial reports, Pelthos Therapeutics Inc. (PTHS) has net assets worth $58.25 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($126.43 Million) and total liabilities ($68.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $58.25 Million |
| % of Total Assets | 46.07% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Pelthos Therapeutics Inc. - Net Assets Trend (2021–2024)
This chart illustrates how Pelthos Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pelthos Therapeutics Inc. (2021–2024)
The table below shows the annual net assets of Pelthos Therapeutics Inc. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-2.71 Million | +57.89% |
| 2023-12-31 | $-6.44 Million | -73.87% |
| 2022-12-31 | $-3.71 Million | -0.71% |
| 2021-12-31 | $-3.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pelthos Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1779472000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $613.00 | % |
| Other Components | $18.76 Million | % |
| Total Equity | $-2.71 Million | 100.00% |
Pelthos Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Pelthos Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nordea Invest Basis 3 KL 1
CO:NDIB3KL1
|
$235.42K |
|
ALLERTHAL-WERKE (ATW.SG)
STU:ATW
|
$235.44K |
|
Alternative Investment Corporation
PINK:AIKO
|
$235.47K |
|
Newtek Business Services Corp. 5.50% Notes Due 2026
NASDAQ:NEWTZ
|
$235.51K |
|
Associated Banc-Corp 6.625% Fixed-Rate Reset Subordinated Notes due 2033
NYSE:ASBA
|
$235.33K |
|
Brookfield Infrastructure Finance ULC
NYSE:BIPJ
|
$235.25K |
|
Coop Opsparing Modig
CO:COIMOD
|
$234.96K |
|
Star Minerals Ltd
AU:SMS
|
$234.89K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pelthos Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -6,444,552 to -2,714,054, a change of 3,730,498.
- Net loss of 7,955,338 reduced equity.
- Share repurchases of 166,512 reduced equity.
- New share issuances of 6,054,620 increased equity.
- Other factors increased equity by 5,797,728.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.96 Million | -293.12% |
| Share Repurchases | $166.51K | -6.14% |
| Share Issuances | $6.05 Million | +223.08% |
| Other Changes | $5.80 Million | +213.62% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Pelthos Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-6.38 | $23.85 | x |
| 2022-12-31 | $-6.43 | $23.85 | x |
| 2023-12-31 | $-11.17 | $23.85 | x |
| 2024-12-31 | $-4.62 | $23.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pelthos Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-227.36K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.09 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.74 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.68 Million |
Industry Comparison
This section compares Pelthos Therapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | $58.25 Million | 0.00% | 1.17x | $235.35K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |